RxDoctor Payments Data

Tory Speert, DO

Interventional Pain Medicine · Saratoga Springs, NYNPI 1972843548

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Nevro Corp. at 31.6% of the total. Reporting peaked in 2019 at $2,668 and has fallen 62.8% since, to $991 in 2025.

$11,342in general payments, 2019–2025

Across 244 payments — averaging $46.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$4K
  • Boston Scientific$3K
  • Vertos Medical, Inc.$1K
  • Abbott$1K
  • Saluda Medical Americas, Inc.$640
  • Ferring Pharmaceuticals Inc.$413
  • plus $907 from 18 others

What the payments were for

  • Food & beverage$11,342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,342 in reported general payments places this provider in the 75th percentile of 132 interventional pain medicine providers in New York.

See all interventional pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$211,238
Medicare patients
481
Services billed
2,978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Duloxetine Hcl316$10,961
Gabapentin676$9,391
Pregabalin160$7,964
Celecoxib98$3,558
Lidocaine17$1,053
Diclofenac Sodium58$600
Baclofen29$599
Meloxicam160$581
Tizanidine Hcl31$573
Methocarbamol69$563
Cyclobenzaprine Hcl60$409
Tramadol Hcl21$170
Topiramate12$98
Alprazolam38$91
Prednisone23$59

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Saratoga Springs

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →